Targeting VEGF in lung cancer EXPERT OPINION ON THERAPEUTIC TARGETS Das, M., Wakelee, H. 2012; 16 (4): 395-406


VEGF promotes tumor angiogenesis and is an important target in various malignancies, including NSCLC. AREAS COVERED: Here, the authors review the data that led to the approval of bevacizumab, a monoclonal antibody against VEGF, in the treatment of lung cancer. The authors also review the key results from a number of Phase II and Phase III trials involving other anti-angiogenic agents being studied in NSCLC, including small-molecule tyrosine kinase inhibitors against the VEGF-receptor and vascular-disrupting agents (VDAs). EXPERT OPINION: Results from ongoing studies and the identification of reliable biomarkers remain critical goals in understanding the exact role of these anti-angiogenic agents in the treatment paradigm of NSCLC.

View details for DOI 10.1517/14728222.2012.669752

View details for Web of Science ID 000302458200006

View details for PubMedID 22439677